Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Transl Med. Sep 28, 2026; 12(3): 124005
Published online Sep 28, 2026. doi: 10.5528/wjtm.124005
RAD51 135G>C genetic polymorphism and the risk of prostate cancer
Sanghapriya Pal, Kiran Dahiya, Kumud Dhankhar, Rajeev Atri, Rakesh Dhankhar, Saurabh Maheswari, Hemang Kumar, Aman Chauhan, Shweta Gaur
Sanghapriya Pal, Biochemistry, Maulana Azad Medical College, New Delhi 110002, Delhi, India
Kiran Dahiya, Biochemistry, Pt BD Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India
Kumud Dhankhar, Saurabh Maheswari, JSS Medical College, Mysuru 570015, Karnataka, India
Rajeev Atri, Rakesh Dhankhar, Department of Radiation Oncology, Pt BD Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryāna, India
Hemang Kumar, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, Delhi, India
Aman Chauhan, Biochemistry, Pacific Medical College and Hospital, Udaipur 313001, Rājasthān, India
Shweta Gaur, Biochemistry, Pathkind National Reference Lab, Gurgaon 122015, Haryāna, India
Author contributions: Pal S, Dahiya K, Atri R designed the study, performed the research and drafted the article; Dhankhar K, Dhankhar R, Maheswari S, Kumar H, Chauhan A, and Gaur S had provided intellectual input, helped in statistical analysis and proofreading of article.
AI contribution statement: We have not used AI tool in the preparation of manuscript.
Institutional review board statement: It was part of MD thesis, so, the study was approved by institutional ethics committee and was reviewed by post-graduate board of institution.
Informed consent statement: Informed consent was taken from all the individuals (cases & controls) enrolled in this study.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Individuals enrolled, were informed that their data will be used for research perpose while
Corresponding author: Kiran Dahiya, MD, Professor, Biochemistry, Pt BD Sharma Post Graduate Institute of Medical Sciences, University of Health Sciences, Rohtak 124001, Haryana, India.
kirandahiya_2002@yahoo.com
Received: June 4, 2026
Revised: July 24, 2026
Accepted: July 30, 2026
Published online: September 28, 2026
Processing time: 92 Days and 6.6 Hours
BACKGROUND
Prostate cancer is the second most common cancer in men worldwide. The incidence of this cancer is constantly and rapidly increasing in India. The genetic variations of RAD51 and its paralog may contribute to the development of cancers such as breast, ovarian, endometrial, colorectal, head and neck cancer, and acute leukemia but there is a scarcity of literature regarding the role of RAD51 135G>C polymorphism in prostate cancer.
AIM
To evaluate RAD51 135G>C polymorphism in patients with prostate cancer.
METHODS
For this research, 50 patients of prostate cancer and fifty healthy controls were enrolled. Genotyping for RAD51 135G>C polymorphism was done by polymerase chain reaction-restriction fragment length polymorphism while estimation of serum total prostate specific antigen (PSA) was done by ELISA. The data were analyzed using appropriate statistical tools, considering P < 0.05 as significant.
RESULTS
A significant association of GC genotype with prostate cancer was observed. No significant association of genotype with total PSA level, Gleason’s score and stage of disease (P > 0.05) could be established.
CONCLUSION
There appears to be a role of RAD51 gene polymorphism in prostate cancer, and GC genotype may have an association with prostate cancer.
Core Tip: Prostate cancer is the second most common cancer of men worldwide and it is an important public health concern in India. We compared 50 patients with prostate cancer with 50 healthy controls. The genotyping for RAD51 135 G>C polymorphism was done by polymerase chain reaction-restriction fragment length polymorphism while estimation of serum total prostate-specific antigen was done by ELISA.
